Astria Therapeutics (NASDAQ:ATXS) just reported results for the fourth quarter of 2023.
- Astria Therapeutics reported earnings per share of -86 cents. This was below the analyst estimate for EPS of -78 cents.
- The company did not report any revenue for the quarter.